Equity Research, Broker Reports, and media content on TIGENIX NV

  • Access the latest forecasts, broker valuations, multiples, and video content from the city about TIGENIX NV
  • See live updates from analysts, company announcements, and other news in a personalised/single dashboard

Research, Charts & Company Announcements

Research Tree provides access to ongoing research coverage, media content and regulatory news on TIGENIX NV. We currently have 0 research reports from 0 professional analysts.

Open
0.70
Volume
0.2m
Range
0.70/0.70
Market Cap
175,799,661m
52 Week
0.60/1.20
Date Source Announcement
13Mar17 06:00 GNW TiGenix Announces Top-Line Phase I/II Results of AlloCSC-01 in Acute Myocardial Infarction
09Mar17 06:00 GNW TiGenix Announces Positive Topline Week-104 Data for Cx601 ADMIRE-CD Trial
07Mar17 06:00 GNW TiGenix Receives Positive Feedback from the FDA on Cx601 Global Phase III Trial Protocol
06Mar17 06:00 GNW TiGenix Provides Update on Cx601 Marketing Authorization Application procedure in Europe
01Mar17 06:00 GNW TiGenix to present at Cowen's 37th Annual Health Care Conference in Boston
17Feb17 08:01 GNW Takeda and TiGenix Report New Data Highlighting Maintenance of Long-Term Remission of Complex Perianal Fistulas in Crohn's Disease Patients with Cx601
06Feb17 06:30 GNW TiGenix announces acceptance of Cx601 abstract for oral presentation at 12th Congress of ECCO
  • Frequency of research reports

     

  • Research reports on

    TIGENIX NV

  • Providers covering

    TIGENIX NV

Latest Content

View the latest research, videos, and podcasts for this company.